AYAL Capital Advisors Ltd Acquires New Holdings in Profound Medical Corp. (NASDAQ:PROF)

AYAL Capital Advisors Ltd bought a new position in shares of Profound Medical Corp. (NASDAQ:PROF - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company's stock, valued at approximately $376,000. AYAL Capital Advisors Ltd owned 0.17% of Profound Medical as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PROF. FIL Ltd boosted its holdings in Profound Medical by 16.9% in the 4th quarter. FIL Ltd now owns 1,795,000 shares of the company's stock valued at $13,486,000 after purchasing an additional 260,000 shares in the last quarter. Gagnon Securities LLC boosted its stake in shares of Profound Medical by 12.6% in the fourth quarter. Gagnon Securities LLC now owns 1,652,531 shares of the company's stock valued at $12,411,000 after buying an additional 185,284 shares in the last quarter. Timelo Investment Management Inc. grew its holdings in Profound Medical by 21.3% during the fourth quarter. Timelo Investment Management Inc. now owns 911,761 shares of the company's stock worth $6,847,000 after acquiring an additional 159,954 shares during the period. Gagnon Advisors LLC raised its position in Profound Medical by 20.0% in the fourth quarter. Gagnon Advisors LLC now owns 896,671 shares of the company's stock worth $6,734,000 after acquiring an additional 149,445 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Profound Medical in the fourth quarter valued at $6,577,000. Hedge funds and other institutional investors own 47.86% of the company's stock.

Profound Medical Trading Up 4.6 %

Shares of PROF traded up $0.24 during mid-day trading on Monday, hitting $5.47. The company had a trading volume of 161,232 shares, compared to its average volume of 59,999. Profound Medical Corp. has a 1-year low of $3.90 and a 1-year high of $11.42. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11. The business's 50-day simple moving average is $5.75 and its 200-day simple moving average is $6.80. The stock has a market cap of $164.39 million, a PE ratio of -4.08 and a beta of 0.44.

Profound Medical (NASDAQ:PROF - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.11. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. The company had revenue of $4.18 million for the quarter, compared to the consensus estimate of $5.92 million. Sell-side analysts forecast that Profound Medical Corp. will post -1.12 earnings per share for the current year.

Analyst Ratings Changes

Separately, Lake Street Capital decreased their price target on Profound Medical from $17.00 to $11.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.